Princeton BioMeditech Corporation (PBM) specializes in the development and manufacturing of advanced rapid diagnostic products, focusing on point-of-care testing. The company has created a diverse portfolio of over 70 one-step rapid tests that cater to various medical needs, including cardiac care, infectious diseases, fertility, drugs of abuse, and food safety. Their products are designed for both consumer in-home use and professional on-site applications, emphasizing simplicity and ease of use. Notable offerings include tests for COVID-19, flu, and various tumor markers, showcasing PBM's commitment to providing accessible and reliable diagnostic solutions.

PBM employs patented technologies to ensure the quality and innovation of its diagnostic products. The company’s extensive product catalog includes specialized tests such as the Status First® D-Dimer Immunoassay for cardiac assessment and the BioSign® series for infectious disease detection. Additionally, PBM offers a range of point-of-care analyzers and veterinary diagnostics, further expanding its impact in the healthcare sector. With a focus on research and development, PBM continues to enhance its product offerings, aiming to improve health outcomes through rapid and accurate testing solutions.

United States

Princeton BioMeditech Corporation develops rapid, point-of-care diagnostics. Utilizing its patented technologies, PBM has developed and introduced an extensive menu of over 70 different one-step/rapid tests.COVID-19: EUA (02/2021)

Princeton BioMeditech

Company Details